Skip to main content

With every step forward, there is hope

Every day represents an opportunity to alter the course of serious neurodegenerative diseases and the people they affect – and a responsibility to improve the lives of people, families, and communities around the world. Thanks to an amazing team of researchers, scientists, and relentless curiosity, we have a lot of exciting news to share.

Clinical trials

We are currently exploring the potential of AMX0035 (sodium phenylbutyrate/  taurursodiol) as a treatment option for ALS, Alzheimer's disease, and Wolfram syndrome. Our aim is to expand upon this innovation to address other neurodegenerative diseases.

Pipeline Graphic

In designing our trials, we rely on the input of clinical leaders, advocacy groups, and the neurodegenerative disease community. This collaborative approach has kept people living with neurodegenerative diseases at the center of everything we do, and is something we will continue in future trials. Explore information about our trials and progress to date.

In designing our trials, we rely on the input of clinical leaders, advocacy groups, and the neurodegenerative disease community. This collaborative approach has kept people living with neurodegenerative diseases at the center of everything we do, and is something we will continue in future trials. Explore information about our trials and progress to date.

White logo of centaur

CENTAUR Phase 2 Study

CENTAUR (NCT03127514) was a Phase 2 multicenter trial that included 137 participants in the U.S. and evaluated the safety and efficacy of AMX0035 in ALS. The trial completed in 2019 and showed positive results.

White logo of PHOENIX

PHOENIX Phase 3 Study

PHOENIX (NCT05021536) is a Phase 3, randomized, placebo-controlled trial in more than 70 sites across the U.S. and Europe designed to evaluate the safety and efficacy for AMX0035 in ALS. Recruiting for this trial is ongoing.

White logo of PEGASUS

PEGASUS Phase 2 Study

PEGASUS (NCT03533257) was a Phase 2a, randomized, placebo-controlled study in 95 participants in the U.S., designed to evaluate the safety, tolerability, neurobiological activity, and preliminary clinical efficacy of AMX0035 in a broad range of participants with dementia or mild cognitive impairment due to Alzheimer's disease.

Latest News

Be the change

Amylyx employees on stairs wearing medical masks

Be the change

We've made some great strides in a short amount of time, but there is still a long road ahead. For as long as people have to fight these diseases, we will be relentlessly working towards the development of new therapies. In order to do that, we need your help. If you're just as driven to make an impact, we are looking for people to join our fast-growing team.